Nueli Capital

elsewhere's corpus doesn't include a profile of Nueli Capital (纽尔利资本) itself — no founding story, fund size, or strategy write-up — but it does show up repeatedly in deal and secondary-market coverage. As a buyer, it was the sole LP of an RMB continuation fund created in a 2023 S transaction with SoftBank China Capital, which transferred three unexited portfolio companies into the new vehicle and stayed on as GP; the deal's architect told 暗涌Waves the two firms had crossed paths on multiple projects for years, making the trust needed for such a deal . As a primary investor, Nueli co-led the hundreds-of-millions RMB Series B of EDA company Xingji (芯行纪) alongside Vertex Growth in May 2024 , and it has been a recurring existing investor in Aureka Biotechnologies (寻明生科), following into the generative-antibody company's 2025 Series A and its $100 million Series B reported by 5Y Capital in August 2026 .